The Trump administration is reviving efforts to launch a pilot program that would change payments for drugs purchased through the federal 340B rebate program. The 340B program was created to help hospitals and clinics care for low-income and rural patients. A previously proposed pilot program would allow drug companies to provide rebates in the form of post-dispensing rebates instead of rebates at purchase. The U.S. Health Resources and Services Administration (HRSA) said in a low-key announcement that it is pursuing the rule for the rebate model, although details were not released. This step is listed under "If you fail at first...", indicating a retry after a previous failure.[1]